MX2013008699A - Compuestos para reducir la produccion de beta-amiloide. - Google Patents

Compuestos para reducir la produccion de beta-amiloide.

Info

Publication number
MX2013008699A
MX2013008699A MX2013008699A MX2013008699A MX2013008699A MX 2013008699 A MX2013008699 A MX 2013008699A MX 2013008699 A MX2013008699 A MX 2013008699A MX 2013008699 A MX2013008699 A MX 2013008699A MX 2013008699 A MX2013008699 A MX 2013008699A
Authority
MX
Mexico
Prior art keywords
compounds
reduction
amyloid production
production
amyloid peptide
Prior art date
Application number
MX2013008699A
Other languages
English (en)
Inventor
John E Macor
Yong-Jin Wu
Li Xu
Kenneth M Boy
Jason M Guernon
Jianliang Shi
Yunhui Zhang
Dmitry S Zuev
Lorin A Thompson Iii
Richard E Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2013008699A publication Critical patent/MX2013008699A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee una serie de compuestos de la Fórmula (1) (ver Fórmula) que modulan la producción del péptido ß-amiloide (AP ß) y son útiles para el tratamiento de la enfermedad de Alzheimer y otros trastornos afectados por la producción del péptido ß-amiloide (AP ß).
MX2013008699A 2011-01-28 2012-01-26 Compuestos para reducir la produccion de beta-amiloide. MX2013008699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437279P 2011-01-28 2011-01-28
PCT/US2012/022665 WO2012103297A1 (en) 2011-01-28 2012-01-26 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

Publications (1)

Publication Number Publication Date
MX2013008699A true MX2013008699A (es) 2013-08-21

Family

ID=45688981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008699A MX2013008699A (es) 2011-01-28 2012-01-26 Compuestos para reducir la produccion de beta-amiloide.

Country Status (15)

Country Link
US (1) US8710061B2 (es)
EP (1) EP2668168B1 (es)
JP (1) JP5908499B2 (es)
KR (1) KR20140014152A (es)
CN (1) CN103328451B (es)
AR (1) AR084944A1 (es)
AU (1) AU2012211301B2 (es)
BR (1) BR112013018298A2 (es)
CA (1) CA2825906A1 (es)
EA (1) EA201391097A1 (es)
IL (1) IL226677A (es)
MX (1) MX2013008699A (es)
SG (1) SG191840A1 (es)
TW (1) TW201309655A (es)
WO (1) WO2012103297A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172190A1 (en) 2013-04-15 2014-10-23 E. I. Du Pont De Nemours And Company Fungicidal amides
JP6688503B2 (ja) * 2014-11-21 2020-04-28 大学共同利用機関法人自然科学研究機構 医薬用組成物
WO2016130920A2 (en) * 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
CN105017046A (zh) * 2015-07-15 2015-11-04 上海博康精细化工有限公司 一种4-环丙胺基丁酸乙酯的制备方法
WO2017012559A1 (zh) * 2015-07-21 2017-01-26 广州再极医药科技有限公司 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用
EP3717472B1 (en) * 2017-11-27 2022-07-27 F. Hoffmann-La Roche AG Pyrimidine derivatives
CN116023365A (zh) * 2019-01-29 2023-04-28 轩竹生物科技股份有限公司 己酮糖激酶抑制剂及其用途
CN112028839B (zh) * 2020-09-30 2022-04-12 中国海洋大学 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1318997T1 (sl) 2000-09-15 2006-12-31 Vertex Pharma Pirazolne spojine, uporabne kot inhibitorji protein-kinaze
WO2009084695A1 (ja) 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
US8637525B2 (en) * 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物

Also Published As

Publication number Publication date
CA2825906A1 (en) 2012-08-02
AU2012211301A1 (en) 2013-09-19
WO2012103297A1 (en) 2012-08-02
JP2014503590A (ja) 2014-02-13
TW201309655A (zh) 2013-03-01
AU2012211301B2 (en) 2016-02-25
CN103328451A (zh) 2013-09-25
EA201391097A1 (ru) 2013-11-29
SG191840A1 (en) 2013-08-30
KR20140014152A (ko) 2014-02-05
US20130030011A1 (en) 2013-01-31
CN103328451B (zh) 2015-06-10
EP2668168B1 (en) 2017-03-01
EP2668168A1 (en) 2013-12-04
IL226677A (en) 2014-11-30
BR112013018298A2 (pt) 2016-11-16
US8710061B2 (en) 2014-04-29
JP5908499B2 (ja) 2016-04-26
AR084944A1 (es) 2013-07-10

Similar Documents

Publication Publication Date Title
MX2012000973A (es) Compuestos para la reduccion de produccion de beta- amiloide.
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
MY170713A (en) Treatment protocol of diabetes type 2
TN2012000369A1 (en) 5-alkynyl-pyrimidines
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
NZ708501A (en) Treatment of pulmonary disease
EA201201648A1 (ru) Стимуляторы sgc
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
MX361499B (es) Baricitinib deuterado.
TN2014000095A1 (en) Pharmaceutical compositions
MX2015001246A (es) Ibrutinib deuterado.
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
MX2013000009A (es) Procedimiento de preparacion de la sal de l-arginina de perindoprilo.
PH12015501146A1 (en) Hydantoin derivative
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
TN2011000531A1 (en) 5- alkynyl - pyridines
MX347541B (es) Analogos de acido sialico.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
IN2012DN06600A (es)
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents